Sign In
Buy ME
$0.606
+0 (+0%)
At Close: Sep 16, 2025
23andMe CEO says the company's collaboration with GSK has been more successful than anticipated
07:27pm, Wednesday, 29'th Sep 2021
23andMe CEO Anne Wojcicki joined CNBC's Jim Cramer on Wednesday's episode of "Mad Money," discussing the company's efforts around therapeutic development.
Healthcare is still ‘stuck in a world of white coats': 23andMe CEO
01:30pm, Friday, 24'th Sep 2021
23andMe CEO Anne Wojcicki joins 'Influencers with Andy Serwer' to discuss the politicization of medicine amid the COVID-19 pandemic.
This Biotech Company Could Offer Nearly Unlimited Optionality
06:28am, Saturday, 28'th Aug 2021
Backed by its growing genetic database, 23andMe could take its business in a number of lucrative directions.
2 SPACs That Look Like Bargains After Post-Earnings Drops
06:32am, Sunday, 22'nd Aug 2021
Many recent SPAC IPOs have been hammered, and these two could be worth a closer look.
5 Blazing Stocks to Buy Trading Under $10 With Massive Upside Potential
06:10am, Saturday, 21'st Aug 2021
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Cathie Wood Stocks: What Names Is ARK Invest CEO Buying Now?
01:09pm, Tuesday, 17'th Aug 2021
Cathie Wood continues to pick up stocks through her ARK Invest ETFs and we're taking a look at some of their top investments for Tuesday. The post Cathie Wood Stocks: What Names Is ARK Invest CEO Buyi
ME Stock: The Credit Suisse Call Giving 23andMe a Boost Today
12:27pm, Tuesday, 17'th Aug 2021
23andMe (ME) stock is rising higher on Tuesday after Credit Suisse weighed in on the personal genomics and biotechnology company. The post ME Stock: The Credit Suisse Call Giving 23andMe a Boost Today
Why 23andMe Stock Soared Today
10:56am, Tuesday, 17'th Aug 2021
It's no great secret why Credit Suisse likes 23andMe.
Why 23andMe's Stock Is Trading Higher Tuesday
09:36am, Tuesday, 17'th Aug 2021
23andMe Holding Co. (NASDAQ:ME) shares are trading higher by 6.6% at $7.77 Tuesday morning after Credit Suisse initiated coverage on the stock with an Outperform rating and announced a $13 price tar
23andMe Holding's (ME) CEO Anne Wojcicki on Q1 2022 Results - Earnings Call Transcript
04:36pm, Friday, 13'th Aug 2021
23andMe Holding's (ME) CEO Anne Wojcicki on Q1 2022 Results - Earnings Call Transcript
Consumer genetics company 23andMe loss widens in first earnings report since going public
07:23am, Friday, 13'th Aug 2021
Consumer genetics company 23andMe ME, -3.29% posted its first quarterly earnings as a public company on Friday, after it merged with Richard Branson's pecial-purpose acquisition corporation, or SPAC,
23andMe Reports FY2022 First Quarter Financial Results
07:00am, Friday, 13'th Aug 2021
First quarter revenue up 23% over prior year Strong cash balance of $770 million Continuing to advance therapeutics portfolio to drive future revenue growth
Here's the Biggest Predictor of a SPAC's Success
06:22am, Thursday, 22'nd Jul 2021
There is one factor that is closely correlated with the returns a SPAC produces for investors.
Why Aren't More Companies Using SPACs for Their IPOs?
08:36am, Monday, 19'th Jul 2021
The SPAC boom has died down, but IPOs have not.
23andMe: New Therapeutic Pipeline And PGS Product Growth Catalyzed By +$696M In SPAC Funding
09:29pm, Sunday, 18'th Jul 2021
23andMe Holding Co. is the leading direct-to-consumer genetic testing company entering drug development with data on 11.3M Genotyped Customers and +$696M in SPAC funding. 23andMe's core products inclu
